Summary
Published December 2018.
Nimalan Arinaminpathy and colleagues1 attempted to provide a mathematical approach to estimate the burden of tuberculosis cases in India from drug sales data as an alternative to WHO’s conventional approach. The authors already list several limitations of their approach in estimating the disease burden. On the basis of several years of first-hand operational research experience on tuberculosis in India, I wish to provide insights into further limitations of this approach.
